FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016286557> ?p ?o ?g. }

• W2016286557 endingPage "1054" @default.
• W2016286557 startingPage "1046" @default.
• W2016286557 abstract "BACKGROUND Thalidomide use in cutaneous sarcoidosis is based on data from small case series or case reports. The objective of this study was to evaluate the efficacy and safety of thalidomide in severe cutaneous sarcoidosis. METHODS This study consisted of a randomized, double-bind, parallel, placebo-controlled, investigator-masked, multicenter trial lasting 3 months and an open-label study from month 3 to month 6. Adults with a clinical and histologic diagnosis of cutaneous sarcoidosis were included in nine hospital centers in France. Patients were randomized 1:1 to oral thalidomide (100 mg once daily) or to a matching oral placebo for 3 months. In the course of an open-label follow-up from month 3 to month 6, all patients received thalidomide, 100 mg to 200 mg daily. The proportions of patients with a partial or complete cutaneous response at month 3, based on at least a 50% improvement in three target lesions scored for area and infiltration, were compared across randomization groups. RESULTS The intent-to-treat population included 39 patients. None of them had a complete cutaneous response. Four out of 20 patients in the thalidomide group (20%) vs four out of 19 patients in the placebo group (21%) had a partial cutaneous response at month 3 (difference in proportion of −1% [95% CI, −26% to +24%] for thalidomide vs placebo, P = 1.0). Eight patients with side effects were recorded in the thalidomide group vs three in the placebo group. We observed a large number of adverse event-related discontinuations in patients taking thalidomide in the first 3 months (four patients with thalidomide, zero with placebo) and in the 3 following months (five patients). CONCLUSIONS At a dose of 100 mg daily for 3 months, our results do not encourage thalidomide use in cutaneous sarcoidosis. TRIAL REGISTRY ClinicalTrials.gov; No.: NCT0030552; URL: www.clinicaltrials.gov Thalidomide use in cutaneous sarcoidosis is based on data from small case series or case reports. The objective of this study was to evaluate the efficacy and safety of thalidomide in severe cutaneous sarcoidosis. This study consisted of a randomized, double-bind, parallel, placebo-controlled, investigator-masked, multicenter trial lasting 3 months and an open-label study from month 3 to month 6. Adults with a clinical and histologic diagnosis of cutaneous sarcoidosis were included in nine hospital centers in France. Patients were randomized 1:1 to oral thalidomide (100 mg once daily) or to a matching oral placebo for 3 months. In the course of an open-label follow-up from month 3 to month 6, all patients received thalidomide, 100 mg to 200 mg daily. The proportions of patients with a partial or complete cutaneous response at month 3, based on at least a 50% improvement in three target lesions scored for area and infiltration, were compared across randomization groups. The intent-to-treat population included 39 patients. None of them had a complete cutaneous response. Four out of 20 patients in the thalidomide group (20%) vs four out of 19 patients in the placebo group (21%) had a partial cutaneous response at month 3 (difference in proportion of −1% [95% CI, −26% to +24%] for thalidomide vs placebo, P = 1.0). Eight patients with side effects were recorded in the thalidomide group vs three in the placebo group. We observed a large number of adverse event-related discontinuations in patients taking thalidomide in the first 3 months (four patients with thalidomide, zero with placebo) and in the 3 following months (five patients). At a dose of 100 mg daily for 3 months, our results do not encourage thalidomide use in cutaneous sarcoidosis." @default.
• W2016286557 created "2016-06-24" @default.
• W2016286557 creator A5004319820 @default.
• W2016286557 creator A5008706998 @default.
• W2016286557 creator A5021363063 @default.
• W2016286557 creator A5029139859 @default.
• W2016286557 creator A5035640410 @default.
• W2016286557 creator A5042447894 @default.
• W2016286557 creator A5043446323 @default.
• W2016286557 creator A5048841305 @default.
• W2016286557 creator A5050985511 @default.
• W2016286557 creator A5054745781 @default.
• W2016286557 creator A5062973224 @default.
• W2016286557 creator A5063177685 @default.
• W2016286557 creator A5066493529 @default.
• W2016286557 creator A5068145736 @default.
• W2016286557 creator A5078564033 @default.
• W2016286557 creator A5083736614 @default.
• W2016286557 creator A5087449110 @default.
• W2016286557 creator A5087905603 @default.
• W2016286557 creator A5089382487 @default.
• W2016286557 date "2014-10-01" @default.
• W2016286557 modified "2023-10-14" @default.
• W2016286557 title "A Randomized, Investigator-Masked, Double-Blind, Placebo-Controlled Trial on Thalidomide in Severe Cutaneous Sarcoidosis" @default.
• W2016286557 cites W114071489 @default.
• W2016286557 cites W1860756703 @default.
• W2016286557 cites W1965933950 @default.
• W2016286557 cites W1978847824 @default.
• W2016286557 cites W1980455845 @default.
• W2016286557 cites W1982377576 @default.
• W2016286557 cites W1999543608 @default.
• W2016286557 cites W2013385006 @default.
• W2016286557 cites W2028287202 @default.
• W2016286557 cites W2028705933 @default.
• W2016286557 cites W2031138431 @default.
• W2016286557 cites W2035046934 @default.
• W2016286557 cites W2048251992 @default.
• W2016286557 cites W2069589561 @default.
• W2016286557 cites W2071742211 @default.
• W2016286557 cites W2074387830 @default.
• W2016286557 cites W2094425699 @default.
• W2016286557 cites W2112752789 @default.
• W2016286557 cites W2122408285 @default.
• W2016286557 cites W2130860647 @default.
• W2016286557 cites W2136935645 @default.
• W2016286557 cites W2159746652 @default.
• W2016286557 cites W2162559503 @default.
• W2016286557 cites W3044254922 @default.
• W2016286557 cites W4234328512 @default.
• W2016286557 cites W4235586515 @default.
• W2016286557 cites W4244164401 @default.
• W2016286557 cites W4376595371 @default.
• W2016286557 doi "https://doi.org/10.1378/chest.14-0015" @default.
• W2016286557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24945194" @default.
• W2016286557 hasPublicationYear "2014" @default.
• W2016286557 type Work @default.
• W2016286557 sameAs 2016286557 @default.
• W2016286557 citedByCount "36" @default.
• W2016286557 countsByYear W20162865572015 @default.
• W2016286557 countsByYear W20162865572016 @default.
• W2016286557 countsByYear W20162865572017 @default.
• W2016286557 countsByYear W20162865572018 @default.
• W2016286557 countsByYear W20162865572019 @default.
• W2016286557 countsByYear W20162865572020 @default.
• W2016286557 countsByYear W20162865572021 @default.
• W2016286557 countsByYear W20162865572022 @default.
• W2016286557 crossrefType "journal-article" @default.
• W2016286557 hasAuthorship W2016286557A5004319820 @default.
• W2016286557 hasAuthorship W2016286557A5008706998 @default.
• W2016286557 hasAuthorship W2016286557A5021363063 @default.
• W2016286557 hasAuthorship W2016286557A5029139859 @default.
• W2016286557 hasAuthorship W2016286557A5035640410 @default.
• W2016286557 hasAuthorship W2016286557A5042447894 @default.
• W2016286557 hasAuthorship W2016286557A5043446323 @default.
• W2016286557 hasAuthorship W2016286557A5048841305 @default.
• W2016286557 hasAuthorship W2016286557A5050985511 @default.
• W2016286557 hasAuthorship W2016286557A5054745781 @default.
• W2016286557 hasAuthorship W2016286557A5062973224 @default.
• W2016286557 hasAuthorship W2016286557A5063177685 @default.
• W2016286557 hasAuthorship W2016286557A5066493529 @default.
• W2016286557 hasAuthorship W2016286557A5068145736 @default.
• W2016286557 hasAuthorship W2016286557A5078564033 @default.
• W2016286557 hasAuthorship W2016286557A5083736614 @default.
• W2016286557 hasAuthorship W2016286557A5087449110 @default.
• W2016286557 hasAuthorship W2016286557A5087905603 @default.
• W2016286557 hasAuthorship W2016286557A5089382487 @default.
• W2016286557 hasConcept C126322002 @default.
• W2016286557 hasConcept C141071460 @default.
• W2016286557 hasConcept C142724271 @default.
• W2016286557 hasConcept C168563851 @default.
• W2016286557 hasConcept C197934379 @default.
• W2016286557 hasConcept C202953159 @default.
• W2016286557 hasConcept C204243189 @default.
• W2016286557 hasConcept C204787440 @default.
• W2016286557 hasConcept C27081682 @default.
• W2016286557 hasConcept C2776364478 @default.
• W2016286557 hasConcept C2779609412 @default.
• W2016286557 hasConcept C2781301800 @default.

• next